R&D & Partnerships
Development platforms for next-generation advanced cellular and gene therapies. CAR-T, TIL therapies, and exosomes.
Development Platforms
GaiaCell develops platforms for next-generation advanced cellular and gene therapies. Our development activities encompass three key areas: CAR-T therapies for hematological malignancies, TIL therapies for solid tumors, and exosome technologies for regenerative applications.
We actively seek partners for co-development of innovative therapies. Our infrastructure, GMP capabilities, and regulatory expertise enable a faster transition from bench to bedside.
Development Platforms
Clinical Studies
Ready Infrastructure
Regulatory Support
CAR-T Therapies
CAR-T (Chimeric Antigen Receptor T-cell) therapies are a revolutionary approach to treating hematological malignancies. The patient's own T cells are genetically modified to express a chimeric antigen receptor that recognizes specific tumor antigens.
GaiaCell is developing a manufacturing process for CAR-T cell products in compliance with GMP standards. Our goal is to establish a regionally accessible platform for CAR-T therapy manufacturing, reducing dependence on distant manufacturing centers.
- Genetic engineering of T cells using viral and non-viral vectors
- GMP-compliant manufacturing process development
- Quality control and release testing
- Cryobanking and logistics for clinical centers
- Regulatory support for clinical trials (ATMP)
CAR-T
TILTIL Therapies
TIL (Tumor-Infiltrating Lymphocyte) therapies harness the natural anti-tumor immune cells already present in the patient's tumor tissue. These lymphocytes are isolated from the tumor, expanded ex vivo, and returned to the patient to fight the cancer.
Our development program focuses on optimizing the processes of TIL isolation, expansion, and activation for solid tumors, including melanoma, lung cancer, and other indications.
- TIL isolation from tumor tissue
- Ex vivo expansion in a controlled environment
- Characterization of anti-tumor activity
- Development for solid tumors (melanoma, lung)
- Collaboration with clinical oncology centers
Exosomes
Exosomes are nanoscale extracellular vesicles (30-150 nm) secreted by cells for intercellular communication. They contain bioactive molecules - proteins, lipids, mRNA, and miRNA - that can influence the behavior of target cells.
GaiaCell is developing MSC-based exosome technologies for regenerative applications. MSC-exosomes mediate many of the therapeutic effects of MSCs without the use of whole cells, offering advantages in terms of safety, stability, and scalability.
- Isolation and characterization of MSC-exosomes
- Development of standardized manufacturing processes
- Characterization of bioactive cargo (proteomics, RNA profiles)
- Regenerative applications for tissue repair
- Potential for cell-free therapeutic approaches
ExosomesPartnership Opportunities
We seek strategic partners for co-development of next-generation advanced therapies
Academic Institutions
Joint research projects, access to GMP infrastructure for translational research.
Biotech Companies
Co-development of therapeutic products, technology licensing, and joint commercialization.
Clinical Centers
Clinical trials, early access to innovative therapies for patients.
International Consortia
EU and international projects for development of cellular and gene therapies.
Partnership Establishment Process
Initial Meeting
Feasibility Assessment
Collaboration Agreement
Project Launch
Scientific Publications
Browse our publications, research articles, and presentations at international conferences.
All PublicationsBecome Our R&D Partner
Contact us to discuss opportunities for research collaboration, therapy co-development, or technology licensing.